http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107224441-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 |
| filingDate | 2017-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107224441-B |
| titleOfInvention | Application of miR-194-5p |
| abstract | The invention relates to research on Proliferative Vitreoretinopathy (PVR), in particular to application of miR-194-5p as a treatment drug for proliferative vitreoretinopathy. The invention proves that miR-194-5p can effectively inhibit epithelial-mesenchymal transition in the main pathological change process of PVR in vivo and in vitro through an in vitro cell model and an animal PVR model, the small molecular compound can be locally applied to eyes through intravitreal cavity injection, other side effects brought by systemic administration are not involved, the small molecular compound is expected to become an effective PVR treatment medicine to assist retinal detachment surgery, and miR-194-5p plays a role by down-regulating Zeb 1. |
| priorityDate | 2017-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 232.